Squarepoint Ops LLC Sells 609,711 Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Squarepoint Ops LLC reduced its position in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) by 92.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,668 shares of the company’s stock after selling 609,711 shares during the quarter. Squarepoint Ops LLC owned 0.58% of Citius Pharmaceuticals worth $199,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tower Research Capital LLC TRC raised its stake in Citius Pharmaceuticals by 103.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,212 shares of the company’s stock valued at $33,000 after acquiring an additional 4,168 shares during the period. IFP Advisors Inc increased its holdings in shares of Citius Pharmaceuticals by 21.2% in the fourth quarter. IFP Advisors Inc now owns 40,416 shares of the company’s stock valued at $162,000 after purchasing an additional 7,083 shares during the last quarter. Finally, Fisher Asset Management LLC acquired a new position in shares of Citius Pharmaceuticals in the fourth quarter valued at $51,000. Institutional investors own 16.88% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on CTXR shares. Citigroup cut Citius Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 23rd. Maxim Group lowered Citius Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, May 23rd. Finally, D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Citius Pharmaceuticals in a research report on Thursday, May 15th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Citius Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $54.50.

Citius Pharmaceuticals Stock Down 0.6%

Shares of CTXR opened at $0.85 on Monday. Citius Pharmaceuticals, Inc. has a 12-month low of $0.65 and a 12-month high of $26.25. The business has a 50-day simple moving average of $0.85 and a two-hundred day simple moving average of $2.04.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.19). As a group, analysts expect that Citius Pharmaceuticals, Inc. will post -4.5 EPS for the current fiscal year.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.